SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-102695"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-102695" > Utilization of a ri...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003060naa a2200481 4500
001oai:DiVA.org:uu-102695
003SwePub
008090511s2009 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:118353336
024a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1026952 URI
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1183533362 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Eriksson, Mathildau Karolinska Institutet4 aut
2451 0a Utilization of a right-handed coiled-coil protein from archaebacterium Staphylothermus marinus as a carrier for cisplatin
264 1c 2009
338 a print2 rdacarrier
520 a BACKGROUND: The nano-sized right-handed coiled-coil (RHCC) protein, originating from the archaebacterium Staphylothermus marinus, is stable at high salt concentrations, high temperatures, high pressures and extremes of pH. Its crystal structure reveals four hydrophobic cavities which can incorporate heavy metals. Nano-sized compounds have been used to carry cytotoxic drugs to tumours, avoiding delivery to healthy tissue, in part due to enhanced permeability in tumour blood vessels (enhanced permeability and retention effect). MATERIALS AND METHODS: The ability of RHCC to carry the platinum-containing chemotherapeutic drug cisplatin to cells, while retaining the cytotoxic potential was tested both in vitro and in vivo. RESULTS: RHCC was able to bind and enter cells in vitro and was not severely toxic or immunogenic in mice. Moreover, RHCC incorporated cisplatin, without inhibiting the cytotoxic potential of the drug against tumour cell lines in vitro or in vivo. CONCLUSION: RHCC can be used as a carrier of cisplatin without abrogating the effect of the drug.
653 a RHCC
653 a cisplatin
653 a nano
653 a carrier
653 a MEDICINE
653 a MEDICIN
700a Hassan, Saadiau Uppsala universitet,Klinisk farmakologi,Cancer Pharmacology and Informatics4 aut0 (Swepub:uu)sadihass
700a Larsson, Rolfu Uppsala universitet,Klinisk farmakologi,Cancer Pharmacology and Informatics4 aut0 (Swepub:uu)rolflars
700a Linder, Stigu Karolinska Institutet4 aut
700a Ramqvist, Torbjörnu Karolinska Institutet4 aut
700a Lövborg, Henrik4 aut
700a Vikinge, Trine4 aut
700a Figgemeier, Egbert4 aut
700a Müller, Jürgen4 aut
700a Stetefeld, Jörg4 aut
700a Dalianis, Tinau Karolinska Institutet4 aut
700a Ozbek, Suat4 aut
710a Karolinska Institutetb Klinisk farmakologi4 org
773t Anticancer Researchg 29:1, s. 11-18q 29:1<11-18x 0250-7005x 1791-7530
856u http://ar.iiarjournals.org/content/29/1/11.full.pdf+htmly Fulltext
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-102695
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:118353336

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy